- Home
- NML vs DCTH Comparison
NML vs DCTH Comparison
Compare NML & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- DCTH
- Stock Information
- Founded
- NML 2012
- DCTH 1988
- Country
- NML United States
- DCTH United States
- Employees
- NML N/A
- DCTH N/A
- Industry
- NML Finance/Investors Services
- DCTH Medical/Dental Instruments
- Sector
- NML Finance
- DCTH Health Care
- Exchange
- NML Nasdaq
- DCTH Nasdaq
- Market Cap
- NML 485.0M
- DCTH 394.9M
- IPO Year
- NML N/A
- DCTH N/A
- Fundamental
- Price
- NML $8.65
- DCTH $10.94
- Analyst Decision
- NML
- DCTH Strong Buy
- Analyst Count
- NML 0
- DCTH 4
- Target Price
- NML N/A
- DCTH $24.50
- AVG Volume (30 Days)
- NML 219.3K
- DCTH 819.3K
- Earning Date
- NML 01-01-0001
- DCTH 08-06-2025
- Dividend Yield
- NML 9.75%
- DCTH N/A
- EPS Growth
- NML N/A
- DCTH N/A
- EPS
- NML N/A
- DCTH 0.06
- Revenue
- NML N/A
- DCTH $70,240,000.00
- Revenue This Year
- NML N/A
- DCTH $159.22
- Revenue Next Year
- NML N/A
- DCTH $41.22
- P/E Ratio
- NML N/A
- DCTH $196.43
- Revenue Growth
- NML N/A
- DCTH 491.35
- 52 Week Low
- NML $6.09
- DCTH $8.08
- 52 Week High
- NML $7.33
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- NML 52.99
- DCTH 48.74
- Support Level
- NML $8.54
- DCTH $10.06
- Resistance Level
- NML $8.54
- DCTH $11.31
- Average True Range (ATR)
- NML 0.11
- DCTH 0.48
- MACD
- NML 0.01
- DCTH 0.15
- Stochastic Oscillator
- NML 72.92
- DCTH 72.30
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.